NASDAQ:CALACalithera Biosciences Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Calithera Biosciences Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $5.15 -0.09 (-1.72 %) (As of 07/3/2020 04:00 PM ET) Add Compare Share Today's Range$5.14Now: $5.15▼$5.4050-Day Range$4.96MA: $5.69▼$6.6852-Week Range$2.45Now: $5.15▼$8.18Volume450,201 shsAverage Volume679,035 shsMarket Capitalization$362.77 millionP/E RatioN/ADividend YieldN/ABeta2.21 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. Its lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase II clinical trial to treat solid tumors. The company also offers INCB001158, an oral inhibitor of arginase that is in Phase I/II clinical trial for the treatment of hematology and oncology. The company is also developing CB-280, an oral arginase inhibitor for the treatment of cystic fibrosis; and CB-708, an orally administered small molecule inhibitor of CD73. It has a license agreement with Mars, Inc. to develop and commercialize Symbioscience's portfolio of arginase inhibitors for use in human healthcare. The company also has clinical trial collaboration with Bristol-Myers Squibb Company to evaluate nivolumab in combination with CB-839. In addition, it has a collaboration and license agreement with Incyte Corporation for the research, development, and commercialization of INCB001158, a small molecule arginase inhibitor for the treatment of hematology and oncology. Calithera Biosciences, Inc. was founded in 2010 and is headquartered in South San Francisco, California.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingCalithera Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $8.50, Calithera Biosciences has a potential upside of 65.0% from its current price of $5.15.Amount of Analyst CoverageCalithera Biosciences has only been the subject of 3 research reports in the past 90 days. Previous Next 2.8 Community Rank Outperform VotesCalithera Biosciences has received 325 “outperform” votes. (Add your “outperform” vote.)Underperform VotesCalithera Biosciences has received 251 “underperform” votes. (Add your “underperform” vote.)Community SentimentCalithera Biosciences has received 56.42% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Calithera Biosciences and other stocks. Vote “Outperform” if you believe CALA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CALA will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldCalithera Biosciences does not currently pay a dividend.Dividend GrowthCalithera Biosciences does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Calithera Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $13,741,588.00 in company stock.Percentage Held by InsidersOnly 11.90% of the stock of Calithera Biosciences is held by insiders.Percentage Held by Institutions71.34% of the stock of Calithera Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Calithera Biosciences are expected to grow in the coming year, from ($1.36) to ($1.22) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Calithera Biosciences is -2.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Calithera Biosciences is -2.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCalithera Biosciences has a P/B Ratio of 2.30. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.59 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CALA Previous Symbol CUSIPN/A CIK1496671 Webwww.calithera.com Phone650-870-1000Debt Debt-to-Equity Ratio0.05 Current Ratio8.75 Quick Ratio8.75Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$22.25 million Price / Sales16.30 Cash FlowN/A Price / Cash FlowN/A Book Value$2.24 per share Price / Book2.30Profitability EPS (Most Recent Fiscal Year)($1.90) Net Income$-89,860,000.00 Net MarginsN/A Return on Equity-68.38% Return on Assets-57.43%Miscellaneous Employees90 Outstanding Shares70,440,000Market Cap$362.77 million Next Earnings Date8/13/2020 (Estimated) OptionableOptionable NASDAQ:CALA Rates by TradingView Receive CALA News and Ratings via Email Sign-up to receive the latest news and ratings for CALA and its competitors with MarketBeat's FREE daily newsletter. Calithera Biosciences (NASDAQ:CALA) Frequently Asked Questions How has Calithera Biosciences' stock been impacted by COVID-19 (Coronavirus)? Calithera Biosciences' stock was trading at $5.23 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CALA stock has decreased by 1.5% and is now trading at $5.15. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Calithera Biosciences? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Calithera Biosciences in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Calithera Biosciences. When is Calithera Biosciences' next earnings date? Calithera Biosciences is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Calithera Biosciences. How were Calithera Biosciences' earnings last quarter? Calithera Biosciences Inc (NASDAQ:CALA) announced its earnings results on Thursday, May, 7th. The biotechnology company reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.36) by $0.02. View Calithera Biosciences' earnings history. What price target have analysts set for CALA? 5 Wall Street analysts have issued 12 month price objectives for Calithera Biosciences' stock. Their forecasts range from $6.00 to $10.00. On average, they expect Calithera Biosciences' stock price to reach $8.50 in the next year. This suggests a possible upside of 65.0% from the stock's current price. View analysts' price targets for Calithera Biosciences. Has Calithera Biosciences been receiving favorable news coverage? News headlines about CALA stock have trended negative this week, according to InfoTrie. The research firm ranks the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Calithera Biosciences earned a media sentiment score of -2.8 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 7.0 out of 10, indicating that recent press coverage is likely to have an impact on the company's share price in the near future. View the latest news about Calithera Biosciences. Who are some of Calithera Biosciences' key competitors? Some companies that are related to Calithera Biosciences include MacroGenics (MGNX), Karyopharm Therapeutics (KPTI), Revance Therapeutics (RVNC), Akcea Therapeutics (AKCA), ZEALAND PHARMA/S (ZEAL), Innoviva (INVA), Portola Pharmaceuticals (PTLA), Kiniksa Pharmaceuticals (KNSA), Heron Therapeutics (HRTX), Esperion Therapeutics (ESPR), Amneal Pharmaceuticals (AMRX), Arvinas (ARVN), Tricida (TCDA), Theravance Biopharma (TBPH) and Odonate Therapeutics (ODT). View all competitors. What other stocks do shareholders of Calithera Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Calithera Biosciences investors own include Puma Biotechnology (PBYI), Incyte (INCY), Medivation (MDVN), BioMarin Pharmaceutical (BMRN), Celadon Group (CGI), Dynavax Technologies (DVAX), First Solar (FSLR), Camtek (CAMT), Plug Power (PLUG) and United Continental (UAL). Who are Calithera Biosciences' key executives? Calithera Biosciences' management team includes the following people: Dr. Susan M. Molineaux, Co-Founder, CEO, Pres & Director (Age 66, Pay $887.04k)Mr. Curtis C. Hecht, Chief Bus. Officer (Age 49, Pay $538.17k)Dr. Keith Orford, Chief Medical Officer (Age 48, Pay $793.85k)Ms. Stephanie Wong, Sr. VP of Fin. & Sec. (Age 46)Ms. Jennifer McNealey, VP of Investor Relations & Strategy What is Calithera Biosciences' stock symbol? Calithera Biosciences trades on the NASDAQ under the ticker symbol "CALA." How do I buy shares of Calithera Biosciences? Shares of CALA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Calithera Biosciences' stock price today? One share of CALA stock can currently be purchased for approximately $5.15. How big of a company is Calithera Biosciences? Calithera Biosciences has a market capitalization of $362.77 million and generates $22.25 million in revenue each year. The biotechnology company earns $-89,860,000.00 in net income (profit) each year or ($1.90) on an earnings per share basis. Calithera Biosciences employs 90 workers across the globe. What is Calithera Biosciences' official website? The official website for Calithera Biosciences is www.calithera.com. How can I contact Calithera Biosciences? Calithera Biosciences' mailing address is 343 OYSTER POINT BLVD. SUITE 200, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-870-1000 or via email at [email protected] This page was last updated on 7/4/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
